We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Critical Path, IMI Sign MoU to Speed Drug Development
Critical Path, IMI Sign MoU to Speed Drug Development
June 22, 2011
A new memorandum of understanding (MoU) between the U.S. Critical Path Institute (C-Path) and the EU’s Innovative Medicines Initiative (IMI) may help accelerate drug development by driving agreements on testing methods.